Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronjon Chakraverty

Showing results (41-50 of 80) with videos related to

Pageof 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphomaKirsty J Thomson, Emma C Morris, Adrian Bloor, et al.
Blood|June 28, 2014
A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapyBrian Philip, Evangelia Kokalaki, Leila Mekkaoui, et al.
Transplantation|June 18, 2010
Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantationBen Carpenter, Tanzina Haque, Maria Dimopoulou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphomaKarl S Peggs, Irfan Kayani, Noha Edwards, et al.
Blood|December 16, 2014
CMV promotes recipient T-cell immunity following reduced-intensity T-cell-depleted HSCT, significantly modulating chimerism statusRob S Sellar, Frederick Arce Vargas, Jake Y Henry, et al.
Cancer Research|April 24, 2015
Genetic Regulation of Fate Decisions in Therapeutic T Cells to Enhance Tumor Protection and Memory FormationPedro Veliça, Mathias Zech, Sian Henson, et al.
BMJ Open|January 29, 2025
Multicentre adaptive randomised trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin versus calcineurin inhibitor-based or sirolimus-based post-transplant cyclophosphamide (Methods of T cell Depletion, MoTD trial)Ronjon Chakraverty, Emma Kempshall, Fiona Dignan, et al.
European Journal of Immunology|October 15, 2015
Depletion of CD11c⁺ cells in the CD11c.DTR model drives expansion of unique CD64⁺ Ly6C⁺ monocytes that are poised to release TNF-αShivajanani Sivakumaran, Stephen Henderson, Sophie Ward, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 26, 2014
CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptorSara Ghorashian, Pedro Veliça, Ignatius Chua, et al.
Lancet (London, England)|August 11, 2024
Integrating patient and public involvement and engagement in translational medicineKaren L Shaw, Melanie J Calvert, Persephone Borrow, et al.
Pageof 8

Showing results (41-50 of 80) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphomaKirsty J Thomson, Emma C Morris, Adrian Bloor, et al.
Blood|June 28, 2014
A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapyBrian Philip, Evangelia Kokalaki, Leila Mekkaoui, et al.
Transplantation|June 18, 2010
Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantationBen Carpenter, Tanzina Haque, Maria Dimopoulou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphomaKarl S Peggs, Irfan Kayani, Noha Edwards, et al.
Blood|December 16, 2014
CMV promotes recipient T-cell immunity following reduced-intensity T-cell-depleted HSCT, significantly modulating chimerism statusRob S Sellar, Frederick Arce Vargas, Jake Y Henry, et al.
Cancer Research|April 24, 2015
Genetic Regulation of Fate Decisions in Therapeutic T Cells to Enhance Tumor Protection and Memory FormationPedro Veliça, Mathias Zech, Sian Henson, et al.
BMJ Open|January 29, 2025
Multicentre adaptive randomised trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin versus calcineurin inhibitor-based or sirolimus-based post-transplant cyclophosphamide (Methods of T cell Depletion, MoTD trial)Ronjon Chakraverty, Emma Kempshall, Fiona Dignan, et al.
European Journal of Immunology|October 15, 2015
Depletion of CD11c⁺ cells in the CD11c.DTR model drives expansion of unique CD64⁺ Ly6C⁺ monocytes that are poised to release TNF-αShivajanani Sivakumaran, Stephen Henderson, Sophie Ward, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 26, 2014
CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptorSara Ghorashian, Pedro Veliça, Ignatius Chua, et al.
Lancet (London, England)|August 11, 2024
Integrating patient and public involvement and engagement in translational medicineKaren L Shaw, Melanie J Calvert, Persephone Borrow, et al.
Pageof 8